Vivos Therapeutics enters $5.5M convertible note with V-Co, initial $900k funded

Vivos Therapeutics, Inc.

Note up to $5.5M principal (incl. 10% OID) from V-Co Investors 3 LLC, affiliate of existing investor New Seneca Partners.
Initial $900k funded; additional advances possible until Feb 16, 2026 outside date for proposed equity financing.
Principal converts dollar-for-dollar into equity instruments of proposed Subsequent Financing; no interest unless default (then 15%).
Company expects to close $5.5M equity financing by Feb 16, 2026; note supports that process.

item 1.01 item 2.03 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vivos Therapeutics, Inc. entered into Note with V-Co Investors 3 LLC valued at up to $5,500,000 (effective 2026-01-15).

Action: entry
Agreement: notes offering
Counterparty: V-Co Investors 3 LLC
Value: up to $5,500,000
Effective: 2026-01-15

Exact text from the filing

On January 15, 2026, Vivos Therapeutics, Inc. (the “ Company ”) entered into an unsecured convertible promissory note in favor of V-Co Investors 3 LLC (“ V-Co ”) in the maximum principal amount of up to $5,500,000 (the “ Note ” and the maximum principal amount, inclusive of the original issuance discount described below, the “ Maximum Principal ”).

View on SEC.gov

304 material agreements filed in the last 30 days. Browse all material agreements →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-002557

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.